139 related articles for article (PubMed ID: 28314697)
41. Rivaroxaban protects from the oxysterol-induced damage and inflammatory activation of the vascular endothelium.
Gorzelak-Pabis P; Broncel M; Wojdan K; Gajewski A; Chalubinski M; Gawrysiak M; Wozniak E
Tissue Barriers; 2021 Oct; 9(4):1956284. PubMed ID: 34323663
[TBL] [Abstract][Full Text] [Related]
42. Possible role of rivaroxaban in attenuating pressure-overload-induced atrial fibrosis and fibrillation.
Kondo H; Abe I; Fukui A; Saito S; Miyoshi M; Aoki K; Shinohara T; Teshima Y; Yufu K; Takahashi N
J Cardiol; 2018 Mar; 71(3):310-319. PubMed ID: 28993090
[TBL] [Abstract][Full Text] [Related]
43. Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding.
Hu X; Xiao Y; Yu C; Zuo Y; Yang W; Wang X; Gu B; Li J
Eur J Pharmacol; 2018 Apr; 825():85-91. PubMed ID: 29475063
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Neira V; Corbalán R; Pereira J; Panes O; Garayar B; Aizman A; Llevaneras S; Villarroel L
Rev Med Chil; 2016 Sep; 144(9):1103-1111. PubMed ID: 28060970
[TBL] [Abstract][Full Text] [Related]
45. FXa-induced responses in vascular wall cells are PAR-mediated and inhibited by ZK-807834.
McLean K; Schirm S; Johns A; Morser J; Light DR
Thromb Res; 2001 Aug; 103(4):281-97. PubMed ID: 11562339
[TBL] [Abstract][Full Text] [Related]
46. Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts
Shimizu S; Tojima I; Takezawa K; Matsumoto K; Kouzaki H; Shimizu T
Am J Rhinol Allergy; 2017 Jan; 31(1):13-18. PubMed ID: 28234145
[TBL] [Abstract][Full Text] [Related]
47. Assessment of in vitro effects of direct thrombin inhibitors and activated factor X inhibitors through clot waveform analysis.
Wakui M; Fujimori Y; Katagiri H; Nakamura S; Kondo Y; Kuroda Y; Nakagawa T; Shimizu N; Murata M
J Clin Pathol; 2019 Mar; 72(3):244-250. PubMed ID: 30518630
[TBL] [Abstract][Full Text] [Related]
48. The n-butanol fraction of Naematoloma sublateritium suppresses the inflammatory response through downregulation of NF-κB in human endothelial cells.
Lee YR; Kim KM; Jeon BH; Choi JW; Choi S
Int J Mol Med; 2012 May; 29(5):801-8. PubMed ID: 22344529
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-1beta and interferon-gamma differentially regulate release of monocyte chemotactic protein-1 and interleukin-8 by human bronchial epithelial cells.
van der Velden VH; Verheggen MM; Bernasconi S; Sozzani S; Naber BA; van der Linden-van Beurden CA; Hoogsteden HC; Mantovani A; Versnel M
Eur Cytokine Netw; 1998 Sep; 9(3):269-77. PubMed ID: 9831176
[TBL] [Abstract][Full Text] [Related]
50. Spike Protein Subunits of SARS-CoV-2 Alter Mitochondrial Metabolism in Human Pulmonary Microvascular Endothelial Cells: Involvement of Factor Xa.
Zekri-Nechar K; Zamorano-León JJ; Reche C; Giner M; López-de-Andrés A; Jiménez-García R; López-Farré AJ; Martínez-Martínez CH
Dis Markers; 2022; 2022():1118195. PubMed ID: 36438904
[TBL] [Abstract][Full Text] [Related]
51. Effect of a new inhibitor of factor Xa zifaxaban, on thrombosis in the inferior vena cava in rabbits.
Qiu X; Zhou J; Wang W; Zhao Z; Tang L; Sun S
J Thromb Thrombolysis; 2019 Jan; 47(1):80-86. PubMed ID: 30298304
[TBL] [Abstract][Full Text] [Related]
52. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
53. Genistein inhibits ox-LDL-induced VCAM-1, ICAM-1 and MCP-1 expression of HUVECs through heme oxygenase-1.
Zhang HP; Zheng FL; Zhao JH; Guo DX; Chen XL
Arch Med Res; 2013 Jan; 44(1):13-20. PubMed ID: 23291378
[TBL] [Abstract][Full Text] [Related]
54. Inhibitory Effect of FXa on Secretory Group IIA Phospholipase A2.
Ku SK; Bae JS
Inflammation; 2015; 38(3):987-94. PubMed ID: 25399323
[TBL] [Abstract][Full Text] [Related]
55. The Coagulant Factor Xa Induces Protease-Activated Receptor-1 and Annexin A2-Dependent Airway Smooth Muscle Cytokine Production and Cell Proliferation.
Schuliga M; Royce SG; Langenbach S; Berhan A; Harris T; Keenan CR; Stewart AG
Am J Respir Cell Mol Biol; 2016 Feb; 54(2):200-9. PubMed ID: 26120939
[TBL] [Abstract][Full Text] [Related]
56. Anticoagulant effects of a synthetic peptide containing residues Thr-2253-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation.
Nogami K; Shima M; Nishiya K; Hosokawa K; Saenko EL; Giddings JC; Tanaka I; Yoshioka A
Br J Haematol; 2002 Mar; 116(4):868-74. PubMed ID: 11886394
[TBL] [Abstract][Full Text] [Related]
57. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.
Schenk B; Würtinger P; Streif W; Sturm W; Fries D; Bachler M
Br J Anaesth; 2016 Nov; 117(5):583-591. PubMed ID: 27623677
[TBL] [Abstract][Full Text] [Related]
58. Lyso-Sulfatide Binds Factor Xa and Inhibits Thrombin Generation by the Prothrombinase Complex.
Yegneswaran S; Banerjee Y; Fernández JA; Deguchi H; Griffin JH
PLoS One; 2015; 10(8):e0135025. PubMed ID: 26263376
[TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats.
Dixon-Jimenez AC; Brainard BM; Brooks MB; Nie B; Arnold RD; Loper D; Abrams JC; Rapoport GS
J Vet Emerg Crit Care (San Antonio); 2016 Sep; 26(5):619-29. PubMed ID: 27599304
[TBL] [Abstract][Full Text] [Related]
60. Factor Xa Inhibitor Suppresses the Release of Phosphorylated HSP27 from Collagen-Stimulated Human Platelets: Inhibition of HSP27 Phosphorylation via p44/p42 MAP Kinase.
Tsujimoto M; Kuroyanagi G; Matsushima-Nishiwaki R; Kito Y; Enomoto Y; Iida H; Ogura S; Otsuka T; Tokuda H; Kozawa O; Iwama T
PLoS One; 2016; 11(2):e0149077. PubMed ID: 26867010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
